AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s

12 Sep 2023

Data showing superiority on endoscopic remission and non-inferiority on clinical remission could position AbbVie’s IL-23 inhibitor to move ahead of Stelara in treatment paradigm.

Head to head — AbbVie's Skyrizi prevailed in a head-to-head trial versus Stelara • Source: Shutterstock

AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s

More from Clinical Trials

More from R&D